Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas
| Autor: | Gregory J. Zipfel, Keith M. Rich, John Spencer Evans, Joshua L. Dowling, Clifford G. Robinson, Ralph G. Dacey, Jingxia Liu, Andrew L. Lin, Eric C. Leuthardt, Albert H. Kim, Jiayi Huang, Michael R. Chicoine, Joseph R. Simpson, David Tran, Gerald P. Linette, Robert L. Grubb |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Pathology Oligoastrocytoma Oligodendroglioma Astrocytoma Lower risk Young Adult Clinical Research Internal medicine Humans Medicine Survival rate Pseudoprogression Retrospective Studies Brain Neoplasms business.industry Odds ratio Middle Aged Prognosis medicine.disease Survival Rate Chromosomes Human Pair 1 Disease Progression Female Neurology (clinical) Chromosome Deletion Neoplasm Grading business Chromosomes Human Pair 19 Chemoradiotherapy Follow-Up Studies |
| Zdroj: | Neuro-Oncology. 16:123-130 |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/not142 |
| Popis: | Background. Pseudoprogression (PsP) occurs at a higher rate in glioblastoma multiforme with a methylatedMGMT promoter—a subset with increased sensitivity to chemoradiotherapy and better overall prognosis. In oligodendroglioma (OG) and oligoastrocytoma (OA), presence of 1p/19q codeletions is highly predictive of response to treatment and is often associated with the methylatedMGMTpromoter; hence, this study queries whether the presence of 1p/19q codeletions in OG/OA correlates with a higher rate of PsP following therapy. Methods. A retrospective analysis was performed on all OG/OA in a database of patients with brain tumors who underwent resection of their tumor since 1998. Eighty-eight cases (37 with and 51 without 1p/19q codeletions) met inclusion criteria, and their patient data were analyzed to determine whether the presence of 1p/19q codeletions was associated with PsP and survival. Results. OG/OA (World Health Organization grades II and III) with 1p/19q codeletions had a significantly improved survival (P ¼ .041). Multivariate analysis found that PsP occurred less frequently in OG/OA with 1p/19q codeletions compared with tumors without codeletions (odds ratio, 0.047; 95% confidence interval, 0.005–0.426;P ¼ .0066). The rate of PsP was 19% for the entire cohort, 31% for tumors without codeletions, and 3% for tumors with codeletions. When early posttreatment contrast enhancement developed in tumors with 1p/19q codeletions, it occurred exclusively in tumors that were histologically OA and not OG. Conclusion. Codeletions of 1p/19q are a marker of good prognosis but are unexpectedly associated with a lower likelihood of PsP. PsP does not correlate with sensitivity to treatment and improved survival in OG/OA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|